(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 18 October 2001 (18.10.2001)

(10) International Publication Number WO 01/76601 A3

(51) International Patent Classification7: A61K 31/46, 31/137 // (A61K 31/46, 31:137)

(21) International Application Number: PCT/EP01/03889

(22) International Filing Date: 5 April 2001 (05.04,2001)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0008485.5

7 April 2000 (07.04.2000)

(71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]: Glaxo Wellcome House. Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): JENKINS, Richard, John [GB/US]: SmithKline Beecham Corporation, Five Moore Drive, Research Triangle Park, NC 27709 (US). RICHARDS, David, Hugh [GB/GB]; GlaxoSmithKline. Stockley Park West, Uxbridge, Middlesex UB11 1BT (GB).

- (74) Agent: LEAROYD, Stephanie, Anne: Glaxo Smith Kline, Corprate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU. CZ. DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM. HR. HU. ID. IL. IN, IS, JP, KE, KG, KP, KR. KZ, LC, LK, LR. LS. LT. LU, LV. MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH. GM. KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 21 February 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING SALMETEROL AND IPRATROPIUM

(57) Abstract: The present invention is concerned with pharmaceutical formulations comprising a combination of salmeterol and ipratropium and the use of such formulations in medicine, particularly in the prophylaxis and treatment of respiratory diseases.

INTERNATIONAL SEARCH REPORT

Interr 'anal Application No PCT/EP 01/03889

		1 ,	-1, 00007		
A. CLASSII IPC 7	FICATION OF SUBJECT MATTER A61K31/46 A61K31/137 //(A6	51K31/46,31:137)			
According to	o International Patent Classification (IPC) or to both national cl	assification and IPC			
B. FIELDS	SEARCHED				
Minimum do IPC 7	ocumentation searched (classification system followed by class $A61K$	sitication symbols)			
Documental	tion searched other than minimum documentation to the exten	I that such documents are included in the field	ds searched		
	lata base consulted during the international search (name of deternal, WPI Data, PAJ, CHEM ABS	·			
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT				
Category °	Citation of document, with indication, where appropriate, of	the relevant passages	Relevant to claim No.		
x	MATERA M G ET AL: "A COMBINA CLINICAL RECOMMENDED DOSAGES AND IPRATROPIUM IS NOT MORE E SALMETEROL ALONE IN PATIENTSW OBSTRUCTIVE PULMONARY DISEASE RESPIRATORY MEDICINE, BAILLIE LONDON, GB, vol. 90, no. 8, 1996, pages 4 XP001021998 ISSN: 0954-6111 the whole document WO 99 65464 A (BOEHRINGER ING PHARMA) 23 December 1999 (199	OF SALMETEROL FFECTIVE THAN ITH CHRONIC " RE TINDALL, 97-499, ELHEIM	1-13		
	page 4, line 7-20; claims 1-2				
X Fur	ther documents are listed in the continuation of box C.	Patent family members are li	sted in annex.		
Special categories of cited documents: A* document defining the general state of the art which is not considered to be of particular relevance E* earlier document but published on or after the international filing date L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) O* document referring to an oral disclosure, use, exhibition or other means P* document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search		or priority date and not in conflict cited to understand the principle invention "X" document of particular retevance; cannot be considered novel or ca involve an inventive step when th "Y" document of particular retevance; cannot be considered to involve a document is combined with one of ments, such combination being of in the art. "&" document member of the same pa	 *X* document of particular retevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled 		
	25 October 2001	06/11/2001			
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,		Authorized officer Herrera, S			
i	Fax: (+31-70) 340-3016	nerrera, s			

2

INTERNATIONAL SEARCH REPORT

Interr Conal Application No PCT/EP 01/03889

		PC1/EP 01/03889	
	ion) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category "	Citation of document, with indication, where appropriate, of the relevant passages		Helevant to claim No.
P,X	NOORD VAN J A ET AL: "LONG-TERM TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH SALMETEROL AND THE ADDITIVE EFFECT OF IPRATROPIUM" EUROPEAN RESPIRATORY JOURNAL, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 15, no. 5, May 2000 (2000-05), pages 878-885, XP001021107 ISSN: 0903-1936 abstract		1-13

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 11-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT — Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

Interr 'onal Application No
PCT/EP 01/03889

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9965464	Α .	23-12-1999	DE	19827178 A1	27-04-2000
			DE	19842963 A1	23-03-2000
			AU	4552199 A	05-01-2000
			BR	9911351 A	13-03-2001
			CN	1307470 T	08-08-2001
			EP	1087750 A1	04-04-2001
			NO	20006318 A	30-01-2001
			WO	9965464 A1	23-12-1999

Form PCT/ISA/210 (patent family annex) (July 1992)